Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Malignant neoplasia (late stage) Clinical criteria: Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Insomnia Clinical criteria: Patient must be receiving this drug for the management of insomnia, AND Patient must be receiving long-term nursing care on account of age, infirmity or other condition in a hospital, nursing home or residential facility, AND Patient must have demonstrated, within the past 6 months, benzodiazepine dependence by an unsuccessful attempt at gradual withdrawal.
“Benzodiazepines presumably exert their effects by binding to specific receptors at several sites within the central nervous system either by potentiating the effects of synaptic or pre-synaptic inhibition mediated by gamma-aminobutyric acid or by directly affecting the action potential generating mechanisms.”
“Pharmacokinetic studies have shown that APO-TEMAZEPAM is well absorbed and has a relatively short elimination half-life of approximately 10 hours (range 5 - 15 hours).”
Working under the parallel aged-care framework? Aged-care equivalent →
For prescribing by certain health practitioners Clinical criteria: Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, (iii) an endorsed midwife where patient care is being shared with a medical practitioner.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“The cytochrome P450 system has not been shown to be involved in the disposition of APO- TEMAZEPAM and, unlike many benzodiazepines, pharmacokinetic interactions involving the P450 system have not been observed with APO-TEMAZEPAM.”